An overview of doxorubicin formulations in cancer therapy

Journal of Cancer Research and Therapeutics

Volumn 10, Issue 4, 2014, Pages 853-858

  Rivankar, Sangeeta ^a  

^a Department of Research and Development   (India)

Author keywords

Liposomal; nonpegylated; nudoxa; pegylated

Indexed keywords

DOXORUBICIN; LIPOSOME; MACROGOL; ANTINEOPLASTIC ANTIBIOTIC; MACROGOL DERIVATIVE;

ACUTE LEUKEMIA; ALOPECIA; BONE MARROW DEPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; CONGESTIVE HEART FAILURE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; LEUKEMIA; LUNG CANCER; LYMPHOMA; MOUTH ULCER; NANOENCAPSULATION; NAUSEA; NEPHROTOXICITY; PANDEMIC; REVIEW; SKIN DISEASE; SKIN PIGMENTATION; SOLID TUMOR; TACHYCARDIA; ANALOGS AND DERIVATIVES; NEOPLASMS;

ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; HUMANS; NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 84921385610     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.139267     Document Type: Review

References (42)

1. GLOBOCAN (IARC) Section of Cancer Information. Available from: http://www.globocan.iarc.fr/factsheets/populations/factsheet.aspuno=900. [Last accessed on 2012 May 10].
2. Thigpen JT. Innovations in anthracycline therapy: Overview. Commun Oncol 2005;2:3-7.
3. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin Cancer 2004;100:2052-63.
4. Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 2012;17:160-6.
5. Brockmann H. Anthracyclinones and anthracyclines. (Rhodomycinone, pyrromycinone and their glycosides). Fortschr Chem Org Naturst 1963;21:121-82.
6. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969;11:1101-10.
7. Available from: http://www.usbio.net/misc/doxorubicin. [Last accessed on 2014 Apr 28].
8. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994;45:649-56.
9. Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 1976;36:2891-5.
10. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-doxorubicin-HCL-liposome. [Last accessed on 2013 Oct 24].
11. Balmer C, Valley AW. Basic principles of cancer treatment and cancer chemotherapy. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A Pathophysiologic Approach. 3 rd ed. Stamford, Conn: Appleton and Lange; 1997. p. 2403-65.
12. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: Changing toxicity profiles. Drug Saf 2001;24:903-20.
13. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention. Drug Saf 2000;22:263-302.
14. Maluf FC, Spriggs D. Anthracyclines in the treatment of gynecologic malignancies. Gynecol Oncol 2002;85:18-31.
15. Hortobágyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54:1-7.
16. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
17. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97:2869-79.
18. Birtle AJ. Anthracyclines and cardiotoxicity. Clin Oncol (R Coll Radiol) 2000;12:146-52.
19. Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1999;3:145-59.
20. Tardi PG, Boman NL, Cullis PR. Liposomal doxorubicin. J Drug Target 1996;4:129-40.
21. Hilger RA, Richly H, Grubert M, Oberhoff C, Strumberg D, Scheulen ME, et al. Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil. Int J Clin Pharmacol Ther 2005;43:588-9.
22. Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol 1991;28:302-7.
23. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;54 Suppl 4:15-21.
24. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92.
25. Available from: http://www.doxil.com/. [Last accessed 2012 May 14].
26. Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial Clin Cancer Res 1999;5:3645-52.
27. Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine lewis lung carcinoma: The lack of beneficial effects by coating liposomes with poly (ethylene glycol). J Pharmacol Exp Ther 1997;280:1319-27.
28. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002;4:95-9.
29. Available from: http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Treatmenttypes/Chemotherapy/Individualdrugs/Liposomaldoxorubicin.aspx. [Last accessed on 2012 May 14].
30. The use of liposomal doxorubicin (Myocet®) in the management of metastatic breast cancer, October 2008. Available from: http://www.nyrdtc.nhs.uk/docs/eva/Myocet%202008%20FINAL%20(RDTC).pdf. [Last accessed on 2013 Feb 15].
31. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/human/000297/WC500031808.pdf. [Last accessed on 2013 Oct 24].
32. Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1:297-315.
33. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroR×2005;2:99-107.
34. Shao K, Hou Q, Duan W, Go ML, Wong KP, Li QT. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas. J Control Release 2006;115:150-7.
35. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 2003;92:49-67.
36. Itokazu M, Kumazawa S, Wada E, Wenyi Y. Sustained release of adriamycin from implanted hydroxyapatite blocks for the treatment of experimental osteogenic sarcoma in mice. Cancer Lett 1996;107:11-8.
37. Bromberg L, Alakhov V. Effects of polyether-modified poly (acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J Control Release 2003;88:11-22.
38. Zocchi E, Tonetti M, Polvani C, Guida L, Benatti U, De Flora A. Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model. Proc Natl Acad Sci USA 1989;86:2040-4.
39. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2005;2:108-19.
40. Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly (butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants. J Control Release 2007;117:51-8.
41. Wong HL, Rauth AM, Bendayan R, Wu XY. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm 2007;65:300-8.
42. Dong Y, Feng SS. Poly (d, l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005;26:6068-76.